

Event: IMI impact on dementia, 15 June 2021

SPEAKER BIO



Luc Truyen

Global Head- Development and External
Affairs-Neuroscience
Janssen Pharmaceutical Companies of
Johnson & Johnson

In my current role at Janssen Research & Development, I oversee the Neuroscience early- and late-stage development project portfolio which covers Mood Disorders, Schizophrenia, Neurodegenerative, Neuroinflammatory and Neuromuscular diseases. This includes SPRAVATO® (esketamine) nasal spray, approved for treatment-resistant depression, and PONVORY® (ponesimod), recently approved for relapsing forms of multiple sclerosis (MS). With more than 20 years of diverse experience in the industry, much of my career has focused on Alzheimer's disease research and MS. Together with Mike Hutton (Eli & Lilly) I was the founding chair of the IMI2 Strategic Governing Group Neurodegeneration.